Quest Diagnostics (DGX) Tops Q4 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $4.48, $0.24 better than the analyst estimate of $4.24. Revenue for the quarter came in at $3 billion versus the consensus estimate of $2.93 billion.
Outlook for First Half of 2021
The company estimates its first half 2021 results as follows:
Low | High | |||
Net revenues | $4.85 billion | $5.15 billion | ||
Net revenues increase | 32.9% | 41.1% | ||
Reported diluted EPS | $5.07 | 6.07 | ||
Adjusted diluted EPS | $5.90 | $6.90 | ||
Cash provided by operations | At least $800 million | |||
Capital expenditures | Approximately $200 million | |||
Note on Non-GAAP Financial Measures
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- FatPipe, Inc. (FATN) Reports Q3 EPS of $0.09
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
